Monograph
C09AA06 - Quinapril |
Not porphyrinogenic |
NP |
Rationale
No evidence of CYP-dependent metabolism.
Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea, dyspepsia, and abdominal pain motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
HCl-salt of quinapril, which is a prodrug to the metabolite quinaprilate, which is excreted unchanged by the kidneys.
Therapeutic characteristics
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea, dyspepsia, and abdominal pain. Other common side effects are back pain, myalgia, chest pain, fatigue and asthenia.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Poland
Latvia© NAPOS 2024